Konstantin Krychtiuk (@krychtiukmd) 's Twitter Profile
Konstantin Krychtiuk

@krychtiukmd

MD, PhD. Cardiology / Critical Care Fellow @MedUni_Wien. Former Clinical Research Fellow @DCRINews. Trying to balance research and clinical care.

ID: 909409723379830787

calendar_today17-09-2017 13:32:28

4,4K Tweet

6,6K Followers

4,4K Following

Konstantin Krychtiuk (@krychtiukmd) 's Twitter Profile Photo

What is the chance that my ACS patient will develop cardiogenic shock? well, now there is an app for that! Check out the #Stopshock results and the online calculator!

Konstantin Krychtiuk (@krychtiukmd) 's Twitter Profile Photo

What are the clinical implications of the diagnosis of perioperative and periprocedural myocardial infarction? See our commentary in Nature Reviews Cardiology with Christopher Granger nature.com/articles/s4156…

What are the clinical implications of the diagnosis of perioperative and periprocedural myocardial infarction? 

See our commentary in <a href="/NatRevCardiol/">Nature Reviews Cardiology</a> with <a href="/cbgranger/">Christopher Granger</a> 

nature.com/articles/s4156…
Duke Clinical Research Institute (@dcrinews) 's Twitter Profile Photo

In a new commentary piece for Nature Reviews Cardiology, Konstantin Krychtiuk and Christopher Granger review the definitions of periprocedural and perioperative myocardial infarction while providing implications for clinical practice. Read more: nature.com/articles/s4156…

Harriette Van Spall, MD MPH 🇨🇦 (@hvanspall) 's Twitter Profile Photo

In this RCT of patients with 792 pts diabetes and symptomatic peripheral arterial disease (median BMI <29), the #GLP1RA semaglutide 1 mg sc weekly increased walking distance on a constant load treadmill at 52 weeks #PAD #ACC25

In this RCT of patients with 792 pts diabetes and symptomatic peripheral arterial disease (median BMI &lt;29), the #GLP1RA semaglutide 1 mg sc weekly increased walking distance on a constant load treadmill at 52 weeks #PAD #ACC25
Konstantin Krychtiuk (@krychtiukmd) 's Twitter Profile Photo

Patients with metabolic dysfunction-associated steatotic liver disease (#MASLD) are at at risk for cardiovascular events - see our review article in Current Cardiology Reports lead by our research fellow Johannes Bernhard! #NAFLD #MASH #NASH #fattyliver rdcu.be/egguS

Patients with metabolic dysfunction-associated steatotic liver disease (#MASLD) are at at risk for cardiovascular events - see our review article in Current Cardiology Reports lead by our research fellow Johannes Bernhard! #NAFLD #MASH #NASH #fattyliver

rdcu.be/egguS
Konstantin Krychtiuk (@krychtiukmd) 's Twitter Profile Photo

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy - joint effort by European Society of Cardiology ACVC, EAPCI, EHRA, WG CVPT and EAHAD Kudos to Dan Atar for leading this complex but important project! academic.oup.com/ehjcvp/article…

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy 

- joint effort by <a href="/escardio/">European Society of Cardiology</a> ACVC, EAPCI, EHRA, WG CVPT and <a href="/EAHADnews/">EAHAD</a> 

Kudos to <a href="/dan_atar/">Dan Atar</a> for leading this complex but important project! 

academic.oup.com/ehjcvp/article…
Prof Kausik Ray FMedSci (@profkausikray) 's Twitter Profile Photo

Since 2016 and the Improve It trial we have known that two drugs statins and ezetimibe combination therapy were better than statin monotherapy after an MI for CVD prevention. We also have had PCSK9i trials showing other combination therapies also reduce CVD when added to statins.

Since 2016 and the Improve It trial we have known that two drugs statins and ezetimibe combination therapy were better than statin monotherapy after an MI for CVD prevention. We also have had PCSK9i trials showing other combination therapies also reduce CVD when added to statins.
Konstantin Krychtiuk (@krychtiukmd) 's Twitter Profile Photo

Lipid management post ACS is a team effort! Honored to join Dr Rani Khatib FESC, Prof Lis Neubeck and Lisa Gritzmacher in the #ACNAP #ESCWebinar entitled Lipids and ACS; a multidisciplinary approach to better outcomes This Friday, May 30th, at 6pm CEST! esc365.escardio.org/event/1992

Lipid management post ACS is a team effort! 
Honored to join <a href="/DrRaniKhatib/">Dr Rani Khatib FESC</a>, <a href="/lisneubeck/">Prof Lis Neubeck</a> and Lisa Gritzmacher in the #ACNAP #ESCWebinar entitled 

Lipids and ACS; a multidisciplinary approach to better outcomes

This Friday, May 30th, at 6pm CEST!
esc365.escardio.org/event/1992
Dr Rani Khatib FESC (@drranikhatib) 's Twitter Profile Photo

Join our European Society of Cardiology ACNAPPresident webinar Lipids and acute coronary syndrome; a multidisciplinary approach to better outcomes. Friday 30 May 2025 At 5pm UK time Details and Registeration 👇 esc365.escardio.org/event/1992 Prof Lis Neubeck Konstantin Krychtiuk

Join our <a href="/escardio/">European Society of Cardiology</a> <a href="/ACNAPPresident/">ACNAPPresident</a> webinar 
Lipids and acute coronary syndrome; a multidisciplinary approach to better outcomes.

Friday 30 May 2025
At 5pm UK time
Details and Registeration 👇
esc365.escardio.org/event/1992

 <a href="/lisneubeck/">Prof Lis Neubeck</a>  <a href="/krychtiukmd/">Konstantin Krychtiuk</a>
Dr Rani Khatib FESC (@drranikhatib) 's Twitter Profile Photo

If you missed our webinar titled “Lipids and acute coronary syndrome; a multidisciplinary approach to better outcomes” The recording is now available at European Society of Cardiology 365 website here esc365.escardio.org/event/1992

Konstantin Krychtiuk (@krychtiukmd) 's Twitter Profile Photo

After the European Society of Cardiology webinar is before the webinar! Join us, Nuccia Moricci, Alessandro Sionis and myself on June 20th, 18:00 - 19:00 CEST Title: How to address residual cardiovascular lipid risk beyond statins: the strike-early-and-strong strategy esc365.escardio.org/event/2013?utm…

After the <a href="/escardio/">European Society of Cardiology</a> webinar is before the webinar!

Join us, Nuccia Moricci, <a href="/ASionis/">Alessandro Sionis</a> and myself on
June 20th, 18:00 - 19:00 CEST

Title: How to address residual cardiovascular lipid risk beyond statins: the strike-early-and-strong strategy

esc365.escardio.org/event/2013?utm…